hepurposeofthisreportwastoupdatethe2006InternationalLeagueAgainstEpilepsy(ILAE)reportandidentifythelevelofevidenceforlong-termefficacyoreffectivenessforantiepilepticdrugs(AEDs)asinitialmonotherapyforpatientswithnewlydiagnosedoruntreatedepilepsy.AllapplicablearticlesfromJuly2005untilMarch2012wereidentified,evaluated,andcombinedwiththepreviousysis(Glauseretal.,2006)toprovideacomprehensiveupdate.
Thepriorysismethodologywasutilizedwiththreemodifications:(1)thedetectablenoninferiorityboundaryapproachwasdroppedandbothfailedsuperioritystudiesandprespecifiednoninferioritystudieswereyzedusinganoninferiorityapproach,(2)thedefinitionofanadequatecomparatorwasclarifiedandnowincludesanabsoluteminimumpointestimateforefficacy/effectiveness,and(3)therelationshiptablebetweenclinicaltrialratings,levelofevidence,andconclusionsnolongerincludesarecommendationcolumntoreinforcethatthisreviewofefficacy/evidenceforspecificseizuretypesdoesnotimplytreatmentrecommendations.
Thisevidencereviewcontainsoneclarification:ThecommissionhasdeterminedthatclassIsuperioritystudiescanbedesignedtodetectuptoa20?solute(ratherthanrelative)differenceinthepointestimateofefficacy/effectivenessbetweenstudytreatmentandcomparatorusinganintent-to-treatysis.SinceJuly,2005,threeclassIrandomizedcontrolledtrials(RCT)and11classIIIRCTshebeenpublished.Thecombinedysis(1940-2012)nowincludesatotalof64RCTs(7withclassIevidence,2withclassIIevidence)and11meta-yses.
Newefficacy/effectivenessfindingsincludethefollowing:levetiracetamandzonisamidehelevelAevidenceinswithpartialonsetseizuresandbothethosuximideandvalproicacidhelevelAevidenceinchildrenwithchildhoodabsenceepilepsy.
Therearenomajorchangesinthelevelofevidenceforanyothersubgroup.LevetiracetamandzonisamidejoincarbamazepineandphenytoinwithlevelAefficacy/effectivenessevidenceasinitialmonotherapyforswithpartialonsetseizures.AlthoughethosuximideandvalproicacidnowhelevelAefficacy/effectivenessevidenceasinitialmonotherapyforchildrenwithabsenceseizures,therecontinuestobeanalarminglackofwelldesigned,properlyconductedepilepsyRCTsforpatientswithgeneralizedseizures/epilepsiesandinchildreningeneral.
Thesefindingsreinforcetheneedformulticenter,multinationaleffortstodesign,conduct,andyzefutureclinicallyrelevantadequatelydesignedRCTs.Whenselectingapatient'sAED,allrelevantvariablesandnotjustefficacyandeffectivenessshouldbeconsidered.
查看信源地址
编辑:jiang- 2022-04-13英国竞争监管机构指控辉瑞癫痫药品价格过高
- 2022-04-11上海率先探索异地就医门诊费直接结算
- 2022-04-11FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 2022-04-07罕见病例:自发性颞极性扩张伴癫痫发作
- 2022-04-05癫痫治疗障碍仍难以克服
- 2022-04-04癫痫患者手术评估新型工具
- 上海率先探索异地就医门诊费直接结算
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 罕见病例:自发性颞极性扩张伴癫痫发作
- FDA批准Aptiom用于治疗患者癫痫发作
- 癫痫治疗障碍仍难以克服
- 癫痫患者手术评估新型工具
- 抗癫痫药物预防新发癫痫:任重而道远
- UCB的Vimpat癫痫新适应症在美国获批
- 2013国际抗癫痫联合会抗癫痫药用指南
- 手术学习:颅内脊索瘤内镜下三脑室入路治疗
- 睡觉时突然抽搐 新生儿睡觉抽搐怎么办?
- Circ Ep:左室肥厚高血压患者新发房颤增加SCD风险
- 癫痫饮食有哪些禁忌?
- PLoS ONE:新的合成蛋白能快速激活免疫系统抵抗流感
- GW制药Epidiolex治疗Dret综合征获得欧盟孤儿药资格
- 北京癫痫医院治疗费用
- Diabetes Obes Metab:恩格列净对肝脂肪变性和纤维化标志物的影响及其与心肾结局的关系
- 2016AAN:神经专家发表了有前途的专业见解
- 控制癫痫患者再次抽搐,不包括可选药物?
- JAMA Neurology:左乙拉西坦对阿尔茨海默病患者的认知功能有影响,不伴有癫痫活动
- 癫痫发作对中风患者静脉溶栓的长期转移有效
- 预测癫痫患者再入院风险
- 【用药情报站】临床应用应听取各种药种药物禁忌证?
- 三庚酸酯可治疗1型转运体缺陷综合征
- NeuroImage:纤维球成像可用于癫痫的进展
- 癫痫病的治疗经费
- 癫痫病治疗哪家好玩什么好呢
- 治疗法儿童癫痫病是什么方法比较好呢
- 三十岁男子小脑萎缩无以自理,手术治疗为其重返人生
- 世界癫痫日 | 科学防治 准则诊疗 告别癫痫
- 癫痫病发作是什么病症
- 癫痫病的病因具体分成哪些
- 全「利」控制 升级保护——利必通®分散片中国上市则会
- 癫痫病治疗开支大概多少钱
- 早期癫痫病的呕吐都有什么
- 专家想到你癫痫病的治疗好方法
- 运动控制准不准?到底该做哪种运动控制 ?
- 人类遗忘究竟如何形成及提取?迄今最清晰证据出现!
- 少见的癫痫病症状有哪些
- 癫痫病较常见的病症是什么